Please login to the form below

Not currently logged in
Email:
Password:

AZ and Medimmune bolsters immuno-oncology leadership

Dr Jean-Charles Soria and Dr Geoffrey Kim join the company

AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, respectively.

Kim and his team will focus on the development of the company’s late-stage immuno-oncology combinations programme, aiming to develop combination regimens that will deliver innovative medicines to patients.

He most recently served the US Food and Drug Administration (FDA) as its director, division of oncology products in the office of haematology oncology products since 2015 and also had roles at the National Cancer Institute (NCI).

Soria also taking up a leadership role within AZ’s global biologics research and development arm MedImmune, will lead a team responsible for the group’s strategy, growth, and advancement of the early oncology biologics portfolio.

Prior to joining MedImmune, he served as a professor of medicine and medical oncology at South-Paris University and has also served as chair of the drug development department at the Institut Gustave Roussy - a leading cancer-research institute.

He will join the company in early September succeeding Dr David Berman, who has been appointed to the new role of senior vice president, immuno-oncology franchise.

8th August 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics